Eyelea has being introduced in November 2012. It is expected to be the first choice treatment for Neovascular AMD (instead of Lucentis). This talk discusses the reasons for this change.

1. Dr John ChangDr John Chang
BSc(Med) MBBS(Hons 1), PhD(UNSW), FRANZCO
Consultant Ophthalmic Surgeon & Senior Lecturer, UNSW
Central Coast Eye Specialists

4. 80 mg
At dose of 2 tabs daily
(NB. bottle is wrong)
AREDS formulation

6.  Original dose Zinc (80 mg as Zinc oxide)
 Copper (2 mg as Copper oxide)
 Vitamin E (400 IU)
 Vitamin C (500 mg)
 ie. original AREDS formulation, but without beta-carotene.
+
 Lutein (10 mg) & Zeaxanthin (2 mg)
 Use of fish oil supplement cannot be recommended
based on AREDS2 results.

8. A) Aflibercept is PBS approved for the treatment
of subfoveal CNV of wet AMD.
B) Aflibercept is a chimeric protein with very high
binding affinity toVEGF.
C) Aflibercept binds toVEGF-A,VEGF-B and
Placental growth factor.
D) Aflibercept is a monoclonal antibody.

9. A) Has longer duration of action than Ranibizumab
(Lucentis).
B) Has longer half life than Bevacizumab (Avastin).
C) Has a higher binding affinity toVEGF than
Ranibizumab or Bevacizumab.
D) Has published clinical trial data to support its
efficacy in the treatment of wet AMD.

10. After 1st
injection

11.  2 weeks after Avastin injection
2 wks

14. Avastin
(4 wks)
Eylea
(4 wks)

17. Left subfoveal CNV
(in context of AMD & choroidal naevus)

18. 2 wks

20. 2 weeks post-Lucentis
LVA 6/12

26. A) Fluorescein angiogram (FFA) is essential prior to the
commencement of therapy.
B) All patients with wet AMD should now be treated with
Aflibercept.
C) Patients should be given the choice of anti-VEGF agent
when it exists, after carefully considering the individual
circumstances of the person and with appropriate discussion
and advice from their ophthalmologist.
D) A and B.
E) A and C.

27. 2 wks
6 wks
2 wks post-Avastin 0.07 mL
6 wks post-Avastin 0.07 mL

28. 4 wks post-Eylea #1
4 wks post-Eylea #3

29.  AREDS2: MacuVision Plus or Macutec Essentials.
 Eylea is an important step in the evolution of
therapy for exudative AMD.
 More “choice” of therapy for wet AMD.
 Multiple issues to consider in recommending
best treatment for particular patient.